Breaking FDA News for Triple Negative Breast Cancer: You Can Now Skip Chemotherapy
If you have triple negative breast cancer, this is the most important update you will read this month. On May 22nd, 2026, the FDA approved Datroway (datopotamab deruxtecan) as a first-line treatment for metastatic or unresectable triple negative breast cancer in patients who are not candidates for PD-1 blockers like Keytruda. For the roughly 40,000 people diagnosed with triple negative cancer in the United States every year — about 15% of all breast cancer cases — this changes the treatment conversation entirely. You no longer have to start with standard chemotherapy and wait for it to fail before accessing this much better option.
What Datroway Is and Who It Is For
Datroway is an antibody drug conjugate, or ADC — a targeted therapy that delivers a chemotherapy payload directly to cancer cells. It is not new. It has been used in other settings and has a well-established profile. What is new is this specific approval for first-line triple negative breast cancer in patients who are metastatic or unresectable and not candidates for Keytruda.
That last qualifier covers approximately 70% of triple negative breast cancer cases. So for the majority of people with a TNBC diagnosis, this approval is directly relevant right now.
What the Trial Data Shows
This approval is based on the Tropion Breast-02 trial, which reduced the risk of disease progression by 43% compared to standard chemotherapy, and the risk of death by 21%. The trial enrolled 644 participants in a randomized 1-to-1 design against investigator-choice standard of care chemotherapy. That is a robust trial by any standard.
The NCCN has already added Datroway as a preferred category 1 recommendation. That means your oncologist should already be aware of this change and there is no clinical reason to hesitate.
How This Compares to Trodelvy
Trodelvy — sacituzumab govitecan — was the established ADC option for triple negative breast cancer for five years before Datroway got its first approval in Jan 2025. At ESMO in 2025, Trodelvy's Ascent-03 trial in first-line TNBC did not meet statistical significance for overall survival against chemotherapy. That is a meaningful distinction.
Trodelvy does have a positive readout in combination with Keytruda for PD-L1-positive TNBC, and that combination has already been submitted to the FDA with a decision expected in the second half of 2026. But as it stands today, Datroway shows stronger standalone efficacy in this first-line setting than the combination of Trodelvy with Keytruda is likely to.
What This Means for You Right Now
Before today, the standard path for metastatic or unresectable TNBC was to go through chemotherapy first, wait for significant progression, and only then access a drug like Datroway. That delay and detour is no longer necessary.
As of May 22nd, 2026, you can go straight to Datroway as your first treatment. If your oncologist is not yet aware of this approval, the press release and trial data are linked in the description of the video. Bring it to your next appointment and ask directly to make this the first step for your specific situation.
Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.